Veru Inc. (NASDAQ:VERU - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.61 and traded as low as $0.58. Veru shares last traded at $0.60, with a volume of 1,264,171 shares traded.
Veru Stock Performance
The stock has a market cap of $88.53 million, a P/E ratio of -2.52 and a beta of -0.80. The firm's 50 day moving average is $0.55 and its 200 day moving average is $0.61.
Veru (NASDAQ:VERU - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 128.51%. As a group, analysts expect that Veru Inc. will post -0.22 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in Veru by 37.1% during the 4th quarter. Wells Fargo & Company MN now owns 75,512 shares of the company's stock valued at $49,000 after purchasing an additional 20,430 shares in the last quarter. Integrated Wealth Concepts LLC increased its stake in Veru by 31.3% during the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company's stock valued at $56,000 after purchasing an additional 20,500 shares in the last quarter. Weaver Consulting Group increased its stake in Veru by 27.4% during the 1st quarter. Weaver Consulting Group now owns 88,838 shares of the company's stock valued at $44,000 after purchasing an additional 19,133 shares in the last quarter. Cetera Investment Advisers increased its stake in Veru by 26.1% during the 4th quarter. Cetera Investment Advisers now owns 95,210 shares of the company's stock valued at $62,000 after purchasing an additional 19,724 shares in the last quarter. Finally, NewEdge Advisors LLC increased its stake in Veru by 2,500.0% during the 4th quarter. NewEdge Advisors LLC now owns 130,000 shares of the company's stock valued at $85,000 after purchasing an additional 125,000 shares in the last quarter. Institutional investors own 47.16% of the company's stock.
About Veru
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Read More
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
